Nicola Fenwick BMedSc

Nicola Fenwick

Institute of Cancer and Genomic Sciences
Trial Management Team Leader

Contact details

Telephone
+44 (0)121 415 8782
Fax
+44 (0)121 414 3700
Email
n.fenwick@bham.ac.uk
Address
Cancer Research UK Clinical Trials Unit
Sir Robert Aitken Institute for Clinical Research
Institute of Cancer and Genomic Sciences
University of Birmingham
Vincent Drive
Birmingham, B15 2TT

Nicola Fenwick is team manager for the Childrens Cancer Trials Team (CCTT) at the Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences.

Qualifications

  • BMedSc (Hons) Medical Science 2000

Biography

Nicola Fenwick graduated with a BMedSc (Hons) from the University of Birmingham in 2000. She then went to work as a graduate technician at the Binding Site Ltd, where she was responsible for the development of diagnostic kits. She then returned to the University of Birmingham in 2004 as a Trial Monitor for the Cancer Research UK Clinical Trials Unit (CRCTU).

In 2005 Nicola was appointed as a Trial Coordinator within CRCTU and was made responsible for the management of two large, multi-centre, clinical trials looking at the effects of chemotherapy regimens in breast cancer.

She was then appointed as a Senior Trial Coordinator in 2008, leading Leukemia and Lymphoma Research’s Early Phase Trials Team (LLR ETT). Since its inception the LLR ETT has supported over 15 UK Investigators apply for clinical grant funding for early phase clinical trials.

At the beginning of 2011 Nicola was appointed Team leader and helped secure an award to expand the LLR ETT and establish the LLR Therapy Acceleration Programme Team within CRCTU.

In May 2014 she was appointed Team Leader for the Children’s Cancer Trials Team at CRCTU. Helping to deliver the national portfolio of trials for children with cancer. 

Research

Research Themes

Clinical Trials. Children’s, Paediatric, Cancer, Haematology, Lymphoma, Breast Cancer.

Other activities

Committee and Group Membership

  • National Cancer Research Institute Haemato-Oncology Clinical Studies Group Project Officer 2008 - 2014
  • National Cancer Research Institute (NCRI) Children’s Cancer and Leukaemia Clinical Studies Group New Agents sub-group member
  • Member of the Innovative Therapies for Children with Cancer (ITCC) Sponsors Committee (and associated working groups
  • Member of European Soft Tissue Sarcoma Studies Group (EpSSG)
  • Member of Euro Ewing Consortium (EEC)
  • Member of International Society of Paediatric Oncology Epithelial Liver Tumour Group (SIOPEL)
  • Member of International Society of Paediatric Oncology European Neuroblastoma Research Network (SIOPEN)

Publications

McCabe M, Kirton L, Khan M, Fenwick N, Strauss SJ, Valverde C, Mata C, Gaspar N, Luksch R, Longhi A, Dirksen U, Phillips M, Safwat A, Gelderblom H, Kuehne T, Kanerva J, Westwood AJ, Ferrari S, Whelan J, Wheatley K. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). American Society of Clinical Oncology: Journal of Clinical Oncology. 2022;40(Suppl 17):Abstract No. 11502

Anderton J, Moroz V, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Kaiser S, Fernández-Pinto M, Fenwick N, Evans A, Strauss S, Whelan J, Wheatley K, Brennan B. International randomised controlled trial for the treatment of newly diagnosed Ewing sarcoma family of tumours – Euro Ewing 2012 protocol. Trials. 2020;21:96.

McCabe MG, Kirton L, Khan M, Fenwick N, Dirksen U, Gaspar N, Kanerva J, Kuehne T, Longhi A, Luksch R, Mata C, Phillips M, Safwat A, Strauss SJ, Sundby Hall K, Valverde Morales CM, Westwood AJ, Winstanley M, Whelan J, Wheatley K. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). American Society of Clinical Oncology: Journal of Clinical Oncology. 2020;38(Suppl 15):Abstract No. 11502.

McCabe MG, Moroz V, Khan M, Dirksen U, Evans A, Fenwick N, Gaspar N, Kanerva J, Kühne T, Longhi A, Luksch R, Mata C, Phillips M, Hall KS, Morales CMV, Westwood AJ, Winstanley M, Whelan J, Wheatley K, Consortium EE. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. American Society of Clinical Oncology: Journal of Clinical Oncology. 2019;37(Suppl 15):Abstract No. 11007

Moreno L, Moroz V, Owens C, Couanet DV, Gambert M, Castel V, van Eijkelenburg N, Zwaan CM, Murphy D, Morland B, Gray J, Marshall L, Burchill S, Chesler L, Peet A, Schleiermacher G, Fenwick N, Kearns P, Pearson ADJ, Page 25 of 40 V3.0, 01-Apr-2022 Wheatley K, editors. Temozolomide versus irinotecan-temozolomide for children with relapsed & refractory high risk neuroblastoma (RR-HRNB). Results of the BEACON-Neuroblastoma randomized phase II trial, an ITCC-SIOPEN trial. International Society of Pediatric Oncology; 2019; Lyon, France.

Khan J, Yap C, Clark R, Fenwick N, Marin D (2013): Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design. Trials 2013, 14(Suppl 1):P20 

Earl, H.M. Vallier, A.L. Hiller, L. Fenwick, N. Young, J. Iddawela, M. Abraham, J. Hughes-Davies, L. Gounaris, I. McAdam, K. Houston, S. Hickish, T. Skene, S. Chan, S. Dean, S. Ritchie, D. Laing, R. Harries, M. Gallagher, C. Wishard, G. Dunn, J. Provenzano, E. Caldas, C. for the Neo-tAnGo Investigators.  (2013), Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and aplictaxel for wmen with high-risk early breast cancer (Neo0tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol 2013. Published online December 19, 2013. http://dx.doi.org/10.1016/S1470-2045(13)70554-0 and online comment http://dx.doi.org/10.1016/S1470-2045(13)70584-9

Provenzano, E. A-L Vallier, A.L. Champ, R. Walland, K. Bowden, S. Grier, A, Fenwick, N. Abraham, J. Iddawela, M. Caldas, C. Hiller, L. Dunn, J. Earl, H.M. (2013), A central review of histology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer (2013) 108, 866–872. doi:10.1038/bjc.2012.547 www.bjcancer.com.

H. M. Earl, A. Vallier, L. Hiller, N. Fenwick, M. Iddawela, L. Hughes-Davies, E. Provenzano, K. McAdam, T. Hickish, C. Caldas, for NeotAnGo Investigators (2009), Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR), J Clin Oncol 27:15s, 2009 (suppl; abstr 522)